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ABSTRACT: Pulmonary fibrosis results from excessive fibroblast proliferation and
increased collagen deposition and occurs in chronic lung disease of prematurity (CLD).
Platelet-derived growth factor (PDGF)-BB is mitogenic for fibroblasts and levels are
increased in fibrotic lung disorders. Systemic dexamethasone (DEX) treatment improves
pulmonary function and reduces inflammation in infants with or at risk of CLD.
However, the effect of DEX treatment on fibroblast activity, PDGF-BB and collagen
synthesis in the lungs of CLD patients is uncertain.
Bronchoalveolar lavage (BAL) fluids, obtained from 15 infants at risk of CLD before
and after DEX treatment, were analysed for fibroblast mitogenicity, PDGF-BB,
N-terminal propeptide of collagen type III (PIIINP) and interleukin (IL)-1b levels and
inflammatory cell numbers.
After DEX treatment, the mitogenic activity of BAL fluid for fibroblasts was
not reduced but increased. The change in mitogenicity correlated with a change in
BAL fluid PDGF-BB levels. Furthermore, BAL fluid-induced fibroblast prolifera-
tion was blocked using an inhibitor of the PDGF receptor. DEX treatment did not
influence PIIINP levels, but reduced IL-1b levels and inflammatory cell numbers in
BAL fluid.
This study suggests that dexamethasone treatment does not reduce fibroblast
proliferation despite apparent downregulation of inflammation. The present findings do
not support the use of dexamethasone for prevention of the fibrotic response in infants
at risk of chronic lung disease of prematurity.
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Neonatal respiratory distress syndrome (RDS) is charac-
terised by pulmonary inflammation with neutrophils and
macrophages as the main cell types [1, 2]. RDS can progress
towards chronic lung disease (CLD) of prematurity, also
known as bronchopulmonary dysplasia. Risk factors for the
development of CLD include premature birth with conco-
mitant lung immaturity, mechanical ventilator-induced lung
injury, oxygen toxicity and pulmonary inflammation [3].
Pulmonary fibrosis is characterised by excessive fibroblast
proliferation and increased collagen deposition [4] and is a
common feature in infants dying because of CLD [5]. Increased
pulmonary levels of fibrogenic mediators, such as fibronectin
and transforming growth factor-b1, which increase proliferation
and collagen synthesis by fibroblasts, have been associated
with CLD development [6, 7].
Treatment with systemic dexamethasone (DEX) is com-
monly used in infants with or at risk of CLD and improves
pulmonary function, facilitates weaning from the ventilator
and reduces pulmonary inflammation [8]. However, it has
been suggested that DEX treatment may not inhibit the
development of pulmonary fibrosis in CLD, since it does not
decrease fibronectin concentrations in bronchoalveolar lavage
(BAL) fluid [6]. Conversely, DEX treatment of CLD infants
results in decreased urinary excretion of hydroxyproline,
indicating suppressed collagen synthesis in these infants [9].
However, the specific effect of DEX treatment on lung
collagen synthesis during CLD development remains unclear,
as urinary excretion of hydroxyproline reflects total body
collagen synthesis.
BAL fluid from adults with acute respiratory distress syndrome
(ARDS), who are at risk of pulmonary fibrosis, is mitogenic
for lung fibroblasts in vitro, indicating the presence of soluble
mitogens [10]. Platelet-derived growth factor (PDGF)-BB is
a potent mitogen for fibroblasts and increased pulmonary
levels are associated with pulmonary fibrosis [4]. Additionally,
PDGF-BB has been shown to contribute to BAL fluid-induced
fibroblast proliferation in an animal model of bleomycin-
induced acute lung injury [11]. It has been reported that
expression of PDGF-B messenger ribonucleic acid (mRNA)
by alveolar macrophages, which are considered an important
source of PDGF in the development of pulmonary fibrosis, is
upregulated by DEX [12].
Since excessive fibroblast proliferation is a central event in
the pathogenesis of pulmonary fibrosis and may be driven by
PDGF, it was investigated whether DEX treatment influenced
the fibroblast mitogenic activity of BAL fluid from infants at
risk of CLD. Additionally, the effect of DEX treatment on
PDGF-BB levels in BAL fluid was examined. In order to
analyse the effect of DEX treatment on pulmonary collagen
synthesis, levels of N-terminal-propeptide of collagen type III
(PIIINP) as a marker of collagen type III synthesis and
pulmonary fibrosis were determined [13]. In order to deter-
mine the anti-inflammatory effect of DEX, interleukin (IL)-1b
levels and BAL cell numbers were determined.
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Methods
Patients and dexamethasone regimen
Fifteen ventilated preterm infants with a gestational age of
v30 weeks were included in the study. Criteria for inclusion
were: 1) ventilator dependency because of RDS; and 2)
treatment with DEX because of risk of CLD development.
Informed consent from the parents and approval by the local
medical ethics committees were obtained. All infants received
0.5 mg?kg-1?day-1 DEX sodium phosphate, administered intra-
venously in two doses, for 3 days. This was followed by
0.3 mg?kg-1?day-1 in two divided doses for an additional
3 days, after which the infants were weaned from over
2–4 weeks. At the time that the DEX treatment was started,
sputum cultures were negative for microorganisms. One
patient had a Ureaplasma urealyticum-positive sputum culture
2 days prior to DEX treatment and was treated with
erythromycin. In addition, none of the patients exhibited
signs of active infection at the time the DEX treatment was
initiated. CLD was defined as having an abnormal chest
radiograph and oxygen dependency at 28 days of age [14].
Bronchoalveolar lavage
BAL was performed as described by GRIGG et al. [15],
using two aliquots of 1 ml saline?kg body weight-1 within 24 h
prior to initiating DEX treatment and 24–72 h after initia-
tion of treatment or just before weaning from the ventilator,
whichever occurred first. The BAL samples obtained were
immediately put on ice and processed within 1 h. The recovered
volume was determined and thereafter the samples were
centrifuged (10 min at 4206g at 4uC). The fluid fraction was
separated from the cellular fraction and the BAL fluid stored
in aliquots at -80uC until analysis. Cell numbers were determined
using a haemocytometer. May-Gru¨nwald Giemsa staining was
performed on cytospin preparations and cell differentials were
determined by counting 300 cells per cytospin.
Fibroblast proliferation assay
The human foetal lung fibroblast cell line HFL-1 was cultured
in Dulbecco modified Eagle medium (DMEM) supplemented
with 10% foetal calf serum (FCS), 4 mM ultraglutamine-I
(BioWhittaker Europe, Verviers, Belgium), antibiotics (peni-
cillin, 100 U?mL-1; streptomycin, 100 mg?mL-1) and 15 mM
hydroxyethylpiperazine ethanesulphonic acid (HEPES) buffer.
BAL fluid-induced fibroblast proliferation was determined
using a colorimetric assay based on the uptake and sub-
sequent release of methylene blue [16]. Fibroblasts were
seeded (6 103 cells?well-1) into 96-well microtitre plates in
DMEM/0.4% FCS and allowed to adhere for 24 h. Owing to
limited BAL fluid volumes, initial experiments were per-
formed with serial dilutions of BAL fluid (1/16 to 1/1,024 in
DMEM/0.4% FCS) from infants at risk of CLD. These
experiments revealed that the mitogenic activity of the BAL
fluid was maximal at 1/16 dilution and decreased with
increasing dilution down to medium control (DMEM/0.4%
FCS) levels (data not shown). Therefore, in further studies, a
1/16 dilution of BAL fluid was used to determine the effect
on fibroblast proliferation. Proliferation was determined in
triplicate after 48 h and expressed as percentage change in
mean absorbance from that of cells exposed to DMEM/0.4%
FCS alone. The assay was validated by direct cell counting
and tritium thymidine incorporation.
Analysis of bronchoalveolar lavage fluid
PDGF-BB levels were determined using an enzyme-linked
immunosorbent assay (ELISA; R&D Systems, Abingdon, UK),
PIIINP levels using a radioimmunoassay (Orion diagnostica,
Espoo, Finland) and IL-1b levels by ELISA (Human IL-1b
cytosetTM; Biosource International, Camarillo, CA, USA).
Assays were performed according to the methodology of the
manufacturers. The detection limits were 4.6 pg?mL-1, 0.2 mg?L-1
and 1.6 pg?mL-1, respectively. It was previously demonstrated
that when BAL fluid is analysed in this way, there is a strong
correlation between parameters determined in BAL fluid and
the corrected concentrations of these parameters (i.e. expressed
per millilitre of epithelial lining fluid) [17]. Therefore, no marker
for dilution was used in the present study, and PDGF-BB,
PIIINP and IL-1b levels in BAL fluid are presented as volume
concentrations, which is also in accordance with the most
recent European Respiratory Society task force guidelines on
BAL in children [18].
Inhibition of bronchoalveolar lavage fluid-induced
fibroblast proliferation
Tyrphostin AG1296 is a compound that specifically inhibits
PDGF receptor tyrosine kinase, thereby inhibiting PDGF-
induced proliferation [19]. After adherence of the cells for 24 h,
the medium was changed to DMEM alone for 6 h. There-
after, fresh DMEM containing 30 mM tyrphostin AG1296
(Calbiochem, Darmstadt, Germany) in vehicle (dimethyl-
sulphoxide) or vehicle alone was added for a further 18 h.
The medium was replaced by BAL fluid (known to contain
PDGF-BB) in DMEM/0.4% FCS for 48 h. The assay was
performed in triplicate. As control, HFL-1 cells preincubated
with AG1296 or vehicle were stimulated with 50 ng?mL-1
PDGF-BB (R&D Systems).
Statistical analysis
Patient characteristics and BAL fluid cell numbers are
presented as mean¡SEM. Fibroblast proliferation results and
PDGF-BB, PIIINP and IL-1b levels are presented as median
(range). A paired t-test was used for comparison of values
obtained before and after initiation of DEX treatment.
Pearson9s correlation was used to compare the relationship
between BAL fluid mitogenic activity and PDGF-BB con-
centrations. A p-value ofv0.05 was considered significant.
Results
Patients and dexamethasone regimen
The patients (n=15) had a gestational age of 27.2¡0.3 weeks
(range 26–30 weeks) and a birthweight of 972.6¡66.2 g (range
650–1,529 g). All infants were intubated and ventilated immedia-
tely after birth and all were still ventilator-dependent at
the time that DEX treatment was started. DEX treatment
was initiated at an age of 18.3¡2 days (range 7–33 days)
after birth. In response to the DEX therapy, the pulmonary
function of the infants improved and consequently they were
extubated within days after initiation of treatment. Despite
treatment, all patients developed CLD. One of the infants
died, although this was not during the study period. The
overall survival of the studied infants was 93.3%.
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Bronchoalveolar lavage
BAL was performed at 2.3¡0.2 days (range 1–3 days) after
initiation of DEX treatment. BAL fluid recovery was deter-
mined before and after initiation of treatment. No difference
was observed in BAL fluid recovery before and after initiation
of DEX (40.1¡5.2 and 33.9¡4.2% of initial lavage volume,
respectively). Table 1 shows the numbers and relative composi-
tion of the BAL fluid population. The total number of cells as
well as the number of cells per millilitre of BAL fluid was
significantly decreased after DEX treatment. The percentages
of neutrophils and macrophages in the cell population were
not influenced by DEX treatment. However, the absolute
numbers of macrophages per millilitre of BAL fluid decreased
significantly after DEX. The number of neutrophils per
millilitre of BAL fluid also declined after DEX, but did not
reach significance.
Bronchoalveolar lavage fluid-induced fibroblast proliferation
For the whole group of patients, BAL fluid-induced fibroblast
proliferation increased from 34.7% (7.7–75.3%) before DEX
to 51.2% (17.8–115.1%) after initiation of DEX treatment
(pv0.05). Of the 15 patients studied, 12 showed an increase
and three a decrease in BAL fluid-induced fibroblast prolifera-
tion after initiation of DEX treatment (fig. 1a). Interestingly,
the three patients with decreased BAL fluid mitogenicity
showed the highest mitogenic activity before initiation of
DEX. When fibroblast proliferation was expressed relative to
5% FCS, similar results were obtained (data not shown).
Analysis of bronchoalveolar lavage fluid
A summary of the analysis of the individual BAL fluid
samples is presented in table 2.
DEX treatment did not influence PDGF-BB concentration
in the BAL fluid from the 15 patients before and after DEX
(11.8 (v4.6–92.9) versus 27 (v4.6–80.4) pg?mL BAL fluid-1,
respectively). However, when the mitogenic activity of BAL
fluid from patients decreased after DEX, this decrease was
accompanied by a decrease in PDGF-BB levels (n=3). Of the
12 patients with increased mitogenic activity after DEX, 10
showed an increase in PDGF-BB levels after DEX and one a
minimal decrease; one had undetectable PDGF-BB levels
before and after DEX (fig. 1b). A significant positive correla-
tion was observed between the change in PDGF-BB levels in
BAL fluid and the change in BAL fluid-induced fibroblast
proliferation after initiation of DEX treatment (r=0.7; pv0.01).
PIIINP levels were determined in BAL fluid from 10
patients (based on sample availability). DEX treatment did
not significantly change the levels of PIIINP in this group of
10 patients (10.5 (7.6–51.2) mg?L BAL fluid-1 before DEX
versus 11.5 (6–215) mg?L BAL fluid-1 after DEX.
Owing to limited amounts of BAL fluid, IL-1b levels were
investigated in eight patients. A significant decrease in IL-1b
levels in BAL fluid was observed after DEX treatment (31.3
(v1.6–78.8) pg?mL BAL fluid-1 before DEX versus v1.6
(v1.6–68.2) pg?mL BAL fluid-1 after DEX; pv0.05). Seven
patients showed decreased IL-1b levels after compared to
before DEX treatment. In one patient, IL-1b was undetect-
able before and after DEX treatment.
Inhibition of bronchoalveolar lavage fluid-induced
fibroblast proliferation
In order to determine whether PDGF-BB contributed to
BAL fluid mitogenicity, the PDGF receptor system in fibro-
blasts was blocked using the specific inhibitor tyrphostin
AG1296. Tyrphostin AG1296 was able to inhibit both BAL
fluid- and PDGF-BB-induced fibroblast proliferation (fig. 2).
Tyrphostin AG1296 had no effect on HFL-1 cells after 48 h
in DMEM containing 0.4% FCS compared to preincubation
with vehicle alone.
Table 1. – Effect of dexamethasone (DEX) treatment on the
cell population in neonatal bronchoalveolar lavage fluid
Before DEX After DEX
Total cells 106 cells 1.39¡0.31 0.51¡0.07*
Total cells 106 cells?mL-1 1.74¡0.39 0.9¡0.26*
Macrophages % 43.7¡5.8 39.8¡6.4
Neutrophils % 48.6¡6.0 47.3¡7.0
Macrophages 106 cells?mL-1 0.7¡0.16 0.28¡0.06*
Neutrophils 106 cells?mL-1 0.93¡0.27 0.54¡0.23
Data are presented as mean¡SEM. *: pv0.05.
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Fig. 1. – a) Effect of bronchoalveolar lavage (BAL) fluid (1/16
dilution) on fibroblast proliferation. b) Platelet-derived growth factor
(PDGF)-BB concentration before and after dexamethasone (DEX)
treatment for each individual. Horizontal bars represent medians.
Twelve patients show an increase in BAL fluid mitogenic activity
after DEX and three a decrease. The three patients with a decrease in
BAL fluid mitogenic activity after DEX also show a decrease in
PDGF-BB levels after DEX. Of the 12 patients with increased
mitogenic activity, 10 show increased PDGF-BB levels after DEX
and one a minimal decline in PDGF-BB level after DEX; in one
patient, PDGF-BB was undetectable before and after DEX treatment
and so is shown as being at the detection limit of the assay. *:
pv0.05.
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Discussion
Anti-inflammatory therapy with the corticosteroid DEX
is commonly used in neonatal intensive care units to treat
prematurely born infants with or at risk of CLD. This
treatment has been proven to be beneficial in the short term as
it improves pulmonary function, facilitates weaning from the
ventilator and rapidly reduces pulmonary inflammation [8].
Conversely, there are many side-effects associated with DEX
treatment, such as growth retardation, hyperglycaemia, hyper-
tension, myocardial hypertrophy, gastrointestinal perforation
and neurological impairment [20, 21]. Furthermore, it is not
known whether DEX treatment affects the development of
pulmonary fibrosis in CLD, which may impair pulmonary
function in the long term.
In the present study, it was demonstrated that BAL fluid
from infants developing CLD contains mitogenic activity for
human foetal lung fibroblasts. Recently, CURRIE et al. [22]
demonstrated that BAL fluid from infants developing CLD
is mitogenic for fibroblasts. However, in that study, mice
embryonic fibroblasts were used. The present study is of
importance since human foetal lung fibroblasts were used
and mitogenic activity was also detected in BAL fluid. This
strengthens the findings reported by CURRIE et al. [22],
especially since cells from different species may respond
differently to certain stimuli. A novel finding of the present
study is that treating infants who are developing CLD with
systemic DEX does not reduce BAL fluid mitogenicity for
human foetal lung fibroblasts. This finding is important in the
context of the development of pulmonary fibrosis as excessive
fibroblast proliferation is one of the mechanisms involved in
fibrosis development [4, 10]. Therefore, the present data do
not support the use of DEX to prevent pulmonary fibrosis in
patients at risk of CLD.
In accordance with previous studies [8, 23], DEX treatment
reduced the level of the pro-inflammatory cytokine IL-1b and
inflammatory cell numbers in the BAL samples. It is likely
that this reduction in inflammation contributed to the observed
improvement in pulmonary function in all infants and facilitated
weaning from the ventilator. However, the present study indicates
that, although DEX treatment reduces pulmonary inflam-
mation, it does not reduce pulmonary fibroproliferation in
infants who develop CLD. From the present data, it can even
be speculated that DEX treatment enhances the fibroproli-
ferative response in the lungs of these infants. In this sense,
DEX therapy would have two separate and dissociated
effects: first, reducing inflammation, but secondly, enhancing
fibrosis.
DEX itself may also influence the proliferative activity of
fibroblasts in a direct way. It has been reported that DEX
stimulates the proliferation of rat lung fibroblasts in vitro,
presumably by increasing the expression of the PDGF-a
receptor [24]. In vitro studies with DEX in primary human
foetal lung fibroblasts, however, revealed reduced prolifera-
tion [25]. The BAL samples obtained after treatment in the
present study may have contained DEX as a result of pulmo-
nary vascular leakage, which is clearly associated with CLD
development [3]. Therefore, if DEX were present in the
analysed BAL fluid samples, it may have influenced the BAL
fluid-induced fibroblast proliferation. However, in the present
culture system, DEX itself was unable to stimulate fibroblast
Table 2. – Analysis of bronchoalveolar lavage fluid of individual patients before and after dexamethasone treatment
Patient no. Fibroblast proliferation% PDGF-BB pg?mL-1 PIIINP mg?L-1 IL-1b pg?mL-1
Before After Before After Before After Before After
1 38.9 50.0 15.2 46.1 ND ND 52.3 26.1
2 23.3 38.3 15.1 12.3 ND ND ND ND
3 42.6 58.1 11.8 42.1 7.7 16.2 ND ND
4 45.9 115.1 v4.6 29.7 ND ND ND ND
5 7.7 40.3 v4.6 80.4 7.6 215 78.8 68.2
6 19.5 60.8 v4.6 20.9 51.2 18.2 v1.6 v1.6
7 20.5 30.2 37.1 39.1 43.1 25.9 23.2 5.3
8 34.7 94.4 11.0 30.4 12.3 23.2 ND ND
9 46.0 79.2 12.6 22.8 9.5 6.6 30.7 v1.6
10 28.3 80.8 9.3 27.0 ND ND 48.9 v1.6
11 8.3 17.8 v4.6 v4.6 9.5 6.6 ND ND
12 12.1 44.2 10.5 57.5 ND ND ND ND
13 66.2 51.2 74.0 19.7 9.5 6.8 31.8 v1.6
14 75.3 57.6 13.6 v4.6 24.5 6.0 30.7 v1.6
15 62.2 31.3 92.8 v4.6 11.4 6.3 ND ND
Median 34.7 51.2* 11.8 27.0 10.5 11.5 31.3 v1.6*
Range 7.7–75.3 17.8–115.1 v4.6–92.8 v4.6–80.4 7.6–51.2 6.0–215 v1.6–78.8 v1.6–68.2
PDGF: platelet-derived growth factor; PIINP: N-terminal propeptide of collagen type III; IL: interleukin; ND: not determined.
*: pv0.05 versus before dexamethasone.
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Fig. 2. – Effect of tyrphostin AG1296 (u) on platelet-derived growth
factor (PDGF)-BB (50 ng?mL-1)- and bronchoalveolar lavage (BAL)
fluid-induced fibroblast proliferation as indicated by change in optical
density after methylene blue elution (h: vehicle alone). Data are
presented as mean¡SEM. Results for three individual patients are
shown. *: pv0.05.
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proliferation. Furthermore, addition of the glucocorticoid anta-
gonist RU 38486 to BAL fluid obtained after DEX treatment
did not influence BAL fluid-induced fibroblast proliferation
and neither did the addition of DEX to BAL samples obtained
before DEX treatment (data not shown). Therefore, it is
unlikely that, if DEX were present in BAL fluid, it influenced
the observed BAL fluid-induced fibroproliferation.
Animal models of acute lung injury and pulmonary fibrosis
reveal increased expression of PDGF-B mRNA and PDGF-
BB prior to deoxyribonucleic acid synthesis and tissue repair
[11, 26, 27]. In addition, PDGF-BB has been shown to
contribute to the fibroblast mitogenic activity of BAL fluid
in bleomycin-induced pulmonary fibrosis [11]. Furthermore,
inhibition of PDGF-BB reduces bleomycin-induced pulmo-
nary fibrosis in mice [28]. In line with this is the correlation
found in the present study between the change in BAL fluid-
induced fibroblast proliferation and the concomitant change
in PDGF-BB levels before and after DEX treatment. This
suggests that the increase in PDGF-BB is at least partly
responsible for the observed increase in BAL fluid-induced
fibroblast proliferation after DEX treatment. Blocking the
PDGF receptor system in fibroblasts resulted in a reduction in
BAL fluid-induced fibroblast proliferation. Although this
indicates that PDGF may be an important fibroblast mitogen
in the pathophysiology of CLD, other fibroblast mitogens are
also likely to be involved, since blocking the PDGF receptor
system did not always result in a significant reduction in BAL
fluid-induced fibroblast proliferation.
Alveolar macrophages are considered a major source of
PDGF in pulmonary fibrosis and increased numbers are
present in the pathogenesis of CLD [2, 4]. In the present
study, the BAL cell population contained considerable num-
bers of alveolar macrophages. Therefore, it is likely that these
cells are sources of the PDGF detected in the BAL fluid. It
has been demonstrated that macrophages stimulated with
DEX express increased amounts of PDGF-B mRNA, secrete
increased amounts of PDGF and stimulate fibroblast pro-
liferation and collagen synthesis [12, 29]. Therefore, it may
well be that systemic DEX treatment resulted in an upregula-
tion of PDGF-BB production and secretion by alveolar
macrophages. Activation of such a pathway may result in a
profibrotic environment in the lungs of infants with or at risk
of CLD.
In vitro experiments have demonstrated that DEX is able to
reduce collagen synthesis by fibroblasts [30, 31]. In line with
this, DEX treatment has been demonstrated to decrease total
body collagen synthesis in infants with CLD [9, 32]. However,
no difference was observed in PIIINP levels before and after
DEX treatment, indicating that DEX treatment does not
influence collagen synthesis in the lungs of infants developing
CLD, and, therefore, may not inhibit the development of
pulmonary fibrosis in these infants. This is in agreement with
a recent study showing that DEX treatment does not inhibit
but rather stimulates collagen synthesis by human foetal lung
fibroblasts [25]. Interestingly, CHEN et al. [33] demonstrated
that prenatal DEX administration with prolonged exposure
of preterm rats to hyperoxia resulted in a pulmonary patho-
logical picture similar to CLD and with even greater severity
of septal fibrosis compared to hyperoxia-exposed control rats.
This implies that DEX treatment does not necessarily inhibit
pulmonary collagen synthesis in vivo. However, the fact that
no effect of DEX treatment on PIIINP levels in BAL fluid
was observed may be due to the limited number of patients
and great variability in PIIINP levels, as has also been shown
to exist in BAL fluid from patients with ARDS [10, 34].
Alternatively, an effect of DEX on PIIINP levels may be
obscured due to drainage of PIIINP from the lung by lymph
vessels [35].
In the present study, three patients with relatively high
BAL fluid mitogenicity before initiation of DEX treatment
showed a decrease in BAL fluid mitogenicity after DEX. In
contrast, 12 patients with relatively low BAL fluid mitogeni-
city before DEX showed an increase after DEX. The observed
changes in BAL fluid mitogenicity and PDGF-BB levels after
DEX treatment did not correlate with surfactant treatment,
antenatal steroids, type of ventilation, birthweight or gesta-
tional age (data not shown). Although suggestive, it cannot
be concluded that two different types of response to DEX
treatment occur in infants developing CLD as only a small
group of patients were studied, pulmonary function tests were
not performed and long-term pulmonary outcome was not
examined. Studies including a larger number of patients may
address this question.
It cannot be excluded that the observed differences in the
determined parameters in BAL fluid before and after DEX
treatment simply reflect the natural course of the disease,
since no control patients were included in this study. Because
of the variation in initiation of DEX treatment in the present
patient population (7–33 days after birth) and the fact that
both centres find it unethical to withdraw patients at risk of
CLD from DEX treatment, a placebo control group was not
included. However, regarding the expected and observed anti-
inflammatory effects of DEX treatment and the heterogeneity
of the postnatal ages at which DEX treatment was initiated,
it is tempting to speculate that the effect on BAL fluid
mitogenicity and PDGF-BB levels is likely to be due to DEX
treatment.
In conclusion, the present study suggests that systemic
dexamethasone treatment, as opposed to its anti-inflammatory
action, does not reduce pulmonary fibroproliferation in
chronic lung disease of prematurity. Therefore, this study
does not support the use of dexamethasone for preventing the
fibrotic response in infants at risk of chronic lung disease
of prematurity. Taking the present finding and the already
known complications into account, the present authors
believe that treatment with dexamethasone for the prevention
of chronic lung disease of prematurity should be used with
caution.
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